Given that our data suggest that PTEN-wt prostate cancer cell lines rely on mGluR1 and HER2 to overcome PI3K/mTOR inhibition, we sought to evaluate whether simultaneous inhibition of both signaling pathways would impact on the tumorigenic potential of these cell lines. This evidence concerns the gene PTEN and prostate cancer.